This content is in French.
GLP-1 Analogues and Polycystic Ovary Syndrome: A New Approach Beyond Weight Loss?
8 juin 2026
By Ana Espino | Published on June 08, 2026 | 4 min readPolycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting women of reproductive age. Affecting approximately 12% of women worldwide, it is characterized by a variable combination of hyperandrogenism, ovulatory dysfunction, and metabolic abnormalities. Obesity and insulin resistance, which are frequently associate
By Ana Espino | Published on June 08, 2026 | 4 min read
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting women of reproductive age. Affecting approximately 12% of women worldwide, it is characterized by a variable combination of hyperandrogenism, ovulatory dysfunction, and metabolic abnormalities. Obesity and insulin resistance, which are frequently associated with PCOS, worsen reproductive symptoms and increase the risk of type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease.
Given the limitations of conventional management strategies, which primarily rely on lifestyle modifications and metformin, GLP-1 receptor agonists (GLP-1 RAs)—already widely used for the treatment of diabetes and obesity—have attracted growing interest. A systematic review published in 2025 evaluated the available evidence to assess their impact on the metabolic and reproductive outcomes of women with PCOS.
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting women of reproductive age. Affecting approximately 12% of women worldwide, it is characterized by a variable combination of hyperandrogenism, ovulatory dysfunction, and metabolic abnormalities. Obesity and insulin resistance, which are frequently associated with PCOS, worsen reproductive symptoms and increase the risk of type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease.
Given the limitations of conventional management strategies, which primarily rely on lifestyle modifications and metformin, GLP-1 receptor agonists (GLP-1 RAs)—already widely used for the treatment of diabetes and obesity—have attracted growing interest. A systematic review published in 2025 evaluated the available evidence to assess their impact on the metabolic and reproductive outcomes of women with PCOS.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Celik O, et al. GLP-1 Receptor Analogs: Evidence Linking to Effect on Metabolic and Reproductive Functions in Patients with PCOS and Obesity. Obes Facts
View the source
